Antimicrobial therapy of community-acquired pneumonia. New antibiotics, abreviated course treatment, cost-benefit analysis;Traitement antibiotique des pneumonies communautaires de l'adulte - Apport des nouvelles molécules; place des traitements de durée abrégée; données pharmaco-économiques

Medecine et Maladies Infectieuses

Volumn 31, Issue 4, 2001, Pages 174-180

  Garre M ^a   Potard, M ^a   Hiar, I ^a   Tonnelier, J M ^a   Gentric, A ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Abbreviated course treatment; Antibiotics; Community acquired pneumonia; Comparative study; Cost benefit analysis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFAMANDOLE; CEFDINIR; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; DOXYCYCLINE; FLEROXACIN; GREPAFLOXACIN; ISEPAMICIN; LEVOFLOXACIN; MEROPENEM; NEW DRUG; QUINOLONE DERIVATIVE; ROXITHROMYCIN; SPARFLOXACIN;

ARTICLE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG UTILIZATION; HUMAN; IN VITRO STUDY; INFECTION RISK; PNEUMONIA; RISK FACTOR; TREATMENT PLANNING;

EID: 17944400367     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(01)00181-0     Document Type: Article

References (55)

1. ème Conférence de consensus en thérapeutique anti-infectieuse de la Société de Pathologie Infectieuse de Langue Française Méd Mal Infect. 22:1992;42-46.
2. Geslin P. Centre national de référence des pneumocoques. Rapport d'activité 1997.
3. Note for guidance on statistical principles for clinical trials (1997). http://www.eudra.org/emea. html.
4. Food and Drug Administration. Guidance for industry. Developing antimicrobial drugs. General considerations for clinical trials (1997). http://www.fda.gov/cder/guidance/index.htm.
5. Food and Drug Administration. Guidance for industry. Community-acquired pneumonia - developing antimicrobial drugs for treatment (1998). http://www.fda.gov/cder/guidance/index.htm.
6. Chow A.W., Hall C.B., Klein J.O., Kammer R.B., Meyer R.D., Remington J.S. Evaluation of new anti-infective drugs for the treatment of respiratory tract infection. Clin Infect Dis. 15:(Suppl 1):1992;S62-S68.
7. Smith C., Burley C., Ireson M., et al. Clinical trials of antibacterial agents: a practical guide to design and analysis. J Antimicrob Chemother. 46:1998;467-480.
8. Berntsson E., Lagergard T., Strannegard O., et al. Aetiology of community-acquired pneumonia in out patients. Eur J Clin Microbiol. 5:1986;446-447.
9. Levy M., Dromer F., Brion N., Leturdu F., Carbon C. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest. 92:1998;43-48.
10. Woodhead M.A., Mac Farlane J.T., Mc Cracken J.S., Rose D.H., Finch R.G. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1:1987;671-674.
11. Fang G., Fine M., Orloff J., et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine. 69:1990;307-316.
12. Lim I., Shaw D.R., Stanley D.P., Lumb R., Mc Lennan G. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust. 151:1989;87-91.
13. Bohte R., Vanfurth R., Van Den Brock P.J. Aetiology of community-acquired pneumonia. Thorax. 50:1995;543-547.
14. Porath A., Schlaeffer F., Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect. 34:1997;41-48.
15. Infections respiratoires basses de l'adulte: pneumonie communautaire et bronchite aiguë Méd Mal Infect. 29:1999;237-257.
16. Berman S.J., Sieger B., Geckler R.W., Farkas S.A. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. Cur Ther Res. 58:1997;903-916.
17. Bonfittu P., Lamorgese V., De Vietro T., et al. A randomized rial of cefepime and ceftazidime for the treatment of community-acquired pneumonia. J Chemother. 11:1999;273-277.
18. Colardyn F. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in lower respiratory tract infection. J Chemother. 7:1995;129-135.
19. Brehobl M., Bianchi P., Keyserling C.H., Tack K.J., Griffin T.J. Comparison of cefdinir and cefaclor in the treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 41:1997;1579-1583.
20. Huston M.J., Lentino J.R. Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infections. Clin Therap. 14:1992;595-603.
21. O'Doherty B., Dutchman D.A., Pettit R., Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the reatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 40:(Suppl A):1997;S73-S81.
22. Lode H., Garau J., Grassi C., et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin - acid clavulanic and erythromycin. Eur Respir J. 8:1995;1999-2007.
23. Donowitz G.R., Brandon M.L., Salisbury J.P., et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther. 196:1997;936-953.
24. Zervos M., Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother. 42:1998;729-733.
25. Depalma M., Rocchi D., Canepa G., et al. Single daily dose of cefodizime in patients with community-acquired pneumonia. Clin Ther. 17:1995;413-423.
26. Bohte R., Van't Wout J.W., Lobatto S., et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 14:1995;182-187.
27. O'Doherty B., Muller O. Randomized, multicentric study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mulit to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 17:1998;828-833.
28. Rizzato G., Montemurro L., Fraioli P., et al. Efficacy of a three day course of azithromycin in moderatedly severe community-acquired pneumonia. Eur Respir J. 8:1995;398-402.
29. Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infection. J Antimicrob Chemother. 37:(Suppl C):1996;S93-S101.
30. Hoepelman A.I.M., Sips A.P., Van Helmond J.L.M., et al. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infection. J Antimicrob Chemother. 3:(Suppl E):1993;S147-S152.
31. Hoepelman A.I.M., Müllers M.J., Van Schie M.H., et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid in the treatment of adults with lower respiratory tract infections and effects on long term outcom. Intern J Antimicrob Agents. 9:1998;141-146.
32. Laurent K. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infection. J Antimicrob Chemother. 37:(Suppl C):1996;S115-S124.
33. Morandini G., Perduga M., Zannini G., Foschino M.P., Miragliotta G., Carnimeo N.S. Clinical efficacy of azithromycin in lower respiratory ract infections. J Chemother. 5:1993;32-36.
34. Liippo K., Tala E., Puolijoki H., Brückner O.J., Rodrig J., Smits J.P.H. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. J Infect. 28:1996;131-140.
35. Ramirez J., Unowsky J., Talbot G.H., Zhang H., Townsend L. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther. 21:1998;103-117.
36. File T.M., Segreti J., Dunbar L., et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the reatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 41:1997;1965-1972.
37. Norrby S.R., Petermann W., Willcox P.A., Vetter N., Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 30:1998;397-406.
38. Tremolieres F., de Kock F., Pluck N., Daniel R. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 17:1998;447-453.
39. Aubier M., Verste R., Regarey C., Geslin P., Vercken J.B. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis. 26:1998;1312-1320.
40. Portier H., May T., Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 37:(Suppl A):1996;S83-S91.
41. Örtqvist Ä., Valtonen M., Cars O., et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 110:1996;1499-1506.
42. Grossman R.F., Campbell D.A., Landis S.J., et al. Treatment of community-acquired pneumonia in the elderly: the rôle of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother. 43:1999;549-554.
43. Siegel R.E., Halpern N.A., Almenoff P.L., Lee A., Cashin R., Greene J.G. A prospectived randomized study of in patients IV antibodies for community-acquired pneumonia. The optimal duration of therapy. Chest. 110:1998;965-971.
44. Omidvari K., De Buisblan B.P., Karam G., Nelson S., Haponik E., Summer W. Early transition to oral antibiotic for community-acquired pneumonia: duration of therapy, clinical outcomes and cost analysis. Respir Med. 92:1998;1032-1039.
45. Chan R., Hemeryck L., O'Regan M., Clancy L., Feely J. Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomized controlled trial. Brit Med J. 310:1995;1360-1363.
46. Scott W.G., Cooper B.C., Scott H.M. Pharmacoeconomic evaluation of roxithromycine versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study. Infection. 23:(Suppl 1):1995;S21-S24.
47. Wessels F., Anderson A.N., Ebrahim O. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. South Afr Med J. 88:1998;251-255.
48. Dietrich E.S., Joseph U., Vogel F., Howaldt S., Kullmann K.H., Frank U., Daschner F.D. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. Infection. 2:1999;148-156.
49. Bedos J.P., Leophonte P. Expérience clinique du traitement par l'amoxicilline des pneumonies à pneumocoque de sensibilité diminuée à la pénicilline. Méd Mal Infect. 27:1997;58-67.
50. Piroth L., Martin L., Coulon A., et al. Development of new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother. 10:1999;2484-2492.
51. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 36:1997;243-250.
52. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 275:1996;134-141.
53. Davies T.A., Pankuch G.A., Dewasie B.E., Jacobs M.R., Appelbaum P.C. In vitro development of resistance to five quinolones and amoxycillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother. 43:1999;1177-1182.
54. Ho P.L., Que T.L., Ngai-Chong Tsang D., Ng T.K., Chow K.H., Seto W.H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 43:1999;1310-1313.
55. Chen D.K., Mc Geer A., De Azavedo J., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolons in Canada. N Engl J Med. 341:1999;233-239.